Skip to main content

Table 3 Risk analysis results of gDMRs methylation levels of imprinted genes and CHD occurrence

From: DNA methylation abnormalities of imprinted genes in congenital heart disease: a pilot study

Imprinted genes Quantile percentages Controls
n (%)
CHD
n (%)
Adjusted ORa
(95% CIb)
GRB10 Q1c (< 39.67%) 6(26.1%) 1(4%) 1(reference)
  Q2–Q3 d (39.67%–44%) 11(47.8%) 3(12%) 1.64(0.14–19.39)
  Q4e (> 44%) 6(26.1%) 21(84%) 21.00(2.10–210.14)
MEST Q1 (< 49.36%) 5(22.7%) 1(5%) 1(reference)
  Q2–Q3 (49.36%–56.07%) 12(54.5%) 9(45%) 3.75(0.371–37.95)
  Q4 (> 56.07%) 5(22.7%) 10(50%) 10.00(0.907–110.28)
PEG10 Q1 (< 45.2%) 5(22.7%) 14(56%) 16.80(1.60–176.23)
  Q2–Q3 (45.2%–55.7%) 11(50%) 10(40%) 5.46(0.56–53.52)
  Q4 (> 55.7%) 6(27.3%) 1(4%) 1(reference)
NAP1L5 Q1 (< 67.14%) 6(26.1%) 9(45%) 3.50(0.64–19.20)
  Q2–Q3 (67.14%–71.29%) 10(43.5%) 8(40%) 1.87(0.36–9.64)
  Q4 (> 71.29%) 7(30.4%) 3(15%) 1(reference)
INPP5Ff Q1 (< 70.39%) 4(23.5%) 17(77.3%) 11.06(2.47–49.53)
  Q2–Q4 (≥ 70.39%) 13(76.5%) 5(22.7%) 1(reference)
PLAGL1 Q1 (< 40.76%) 6(24%) 11(42.3%) 11.00(1.06–114.09)
  Q2–Q3 (40.76%–45.82%) 13(52%) 14(53.8%) 6.46(0.68–61.16)
  Q4 (> 45.82%) 6(24%) 1(3.8%) 1(reference)
MEG3f Q1 (< 41.83%) 6(25%) 16(80%) 12.00(2.86–50.31)
  Q2–Q4 (≥ 41.83%) 18(75%) 4(20%) 1(reference)
  1. aOdds ratio
  2. bConfidence interval
  3. c25th percentile
  4. d25th percentile to 75th percentile
  5. e75th percentile. Cut-off value was defined as 25th and 75th percentiles of the control group methylation level. Adjusted for sex by logistic regression
  6. fIndicates that the maximum value of the imprinting gene cases was less than 75% of control group and could not be calculated, so there were divided into two groups